Startups channel feed

Start­up sets out to tack­le the gene ther­a­py man­u­fac­tur­ing cri­sis

5 years ago
Financing

Vik Ba­ja­j's start­up in­cu­ba­tor at Fore­site un­cloaks an im­munol­o­gy play­er with a lead TYK2 in­hibitor in tow

5 years ago
Financing

'Chang­ing the whole game of drug dis­cov­ery': Leg­endary R&D vet Roger Perl­mut­ter leaps back in­to work as a biotech CEO

5 years ago
People

Gene ther­a­pies in the knee? With the help of a small herd of hors­es, a new start­up hopes to crack os­teoarthri­tis

5 years ago
Cell/Gene Tx

Josh Bilenker and Jeff En­gel­man bun­dle a moth­er lode of cash for their stealthy start­up, at­tract­ing a who's who of biotech in­vestors

5 years ago
Bioregnum

A new gene ther­a­py play­er de­buts in LA with 2 start­up VCs at its back, Ab­b­Vie on board with a $90M cash up­front and big plans to up­end the field

5 years ago

Ex­clu­sive: Ohana, Flag­ship's big bet on fer­til­i­ty treat­ments, shuts down and lays off staff af­ter VC pulls the plug

5 years ago

Af­ter fac­ing a 16-month so­journ dur­ing Covid to over­come a stun­ning CRL, lit­tle En­zy­vant says it's back on track — ex­pects mar­ket­ing de­ci­sion lat­er this year

5 years ago
FDA+

Loxo founder Josh Bilenker, No­var­tis on­col­o­gy leader Jeff En­gel­man join forces to de­but can­cer R&D play­er

5 years ago
R&D

Alde­vron founders back a biotech start­up that's look­ing to end the moral de­bate over cell lines once and for all

5 years ago
Cell/Gene Tx

Ver­sant pulls the wraps off of near­ly $1B in 3 new funds out to build the next fleet of biotech star­tups. And this new gen­er­a­tion is built for speed

5 years ago
Financing

Ex­clu­sive: Vik Ba­jaj set out al­most 2 years ago to hatch new com­pa­nies that would shake up health­care with da­ta sci­ence. Here are 5 di­rec­tions he's tak­ing at Fore­site Labs

5 years ago

Har­vard bil­lion­aire Tim Springer has lined up his lat­est biotech launch. And he's re­cruit­ed a star R&D ex­ec to man­age their break­through game plan

5 years ago

Launched by MIT grads, a small start­up gets $20M to back a ro­bot­ics rev­o­lu­tion in cell ther­a­py man­u­fac­tur­ing

5 years ago
Manufacturing

Bet­ting ear­ly on an AI niche, RA Cap­i­tal seeds a young founder's quest to un­lock 'Holy Grail' tar­gets

5 years ago
Financing
AI

Two Church lab vets, a se­cre­tive in­sti­tute and an Is­raeli bil­lion­aire hunt for drugs in the guts of wild an­i­mals

5 years ago
Discovery

GV wa­gers on sea­soned team's in­tranasal 'tem­po­rary' pre­ven­ta­tive ap­proach to virus­es — with ex-Gilead CEO John Mar­tin jump­ing on board

5 years ago
Financing

Neu­ro up­start launch­es out of RA Cap­i­tal’s low-pro­file in­cu­ba­tor with Big Phar­ma vets, clin­i­cal drugs and $80M

5 years ago
Financing

Ex­clu­sive: Mi­crosoft, Sam Alt­man back a new AI biotech up­start

5 years ago
AI

Ex­clu­sive: Two M&A deals and $9B lat­er, Lon­nie Moul­der is ramp­ing up his lat­est biotech start­up. And this one comes with glob­al vi­sion built in

5 years ago

Can a CRISPR start­up suc­ceed where Pfiz­er, Glax­o­SmithK­line, Bio­gen and Genen­tech failed and cure chron­ic pain?

5 years ago
Discovery

Backed by In­di­an biosim gi­ant Bio­con, bis­pecifics play­er Bicara de­buts with $40M and sol­id tu­mors on the radar

5 years ago
Financing

Ex­clu­sive: Ready to ex­it 'qui­et mode,' joint en­ti­ty Ven­tyx de­buts its im­mune mod­u­la­tor pipeline with $114M round

5 years ago
Financing

Khosla joins bet on un­con­ven­tion­al start­up look­ing to send drug de­liv­er­ing ro­bots in­to the brain

5 years ago
First page Previous page 46474849505152 Next page Last page
A service from the Financial Times